AMR SVG Icons location

Hydroxyprogesterone CaproateInjection, USP

  • The first "AP" Rated preservative free generic to Makena*1
  • Vial closure is not made with natural rubber latex

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Vial Opening Size Product Info Availability

250 mg/mL

Supplied As:

1 mL
Single Dose Vial

NDC#: 0517-1767-01

250 mg/mL

1 mL
Single Dose Vial

1 13 mm In Stock
  • Shelf Pack 1
  • Availability In Stock

Wholesaler Numbers

  • Cardinal 5463435
  • McKesson 3917432
  • Morris & Dickson 363259

Case Information

  • Unit of Sale NDC 1767-01
  • Order Size 1
  • Case Size 80
  • Case Per Tier 102

250 mg/mL

Supplied As:

1 mL
Single Dose Vial

NDC#: 0517-1791-01

250 mg/mL

1 mL
Single Dose Vial

1 13 mm Out of Stock
  • Shelf Pack 1
  • Availability Out of Stock


Wholesaler Numbers

  • ABC 10234152
  • Cardinal 5602438
  • McKesson 1520485
  • Morris & Dickson 893115

Case Information

  • Unit of Sale NDC 0517-1791-01
  • Order Size 1
  • Case Size 84
  • Case Per Tier 80

*Makena is a registered trademark of AMAG Pharma USA, Inc.

1Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed August 2018.

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to

For Intramuscular Use Only

Hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
It is not intended for use in women with multiple gestations or other risk factors for preterm birth.


Current or history of thrombosis or thromboembolic disorders; known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions; undiagnosed abnormal vaginal bleeding unrelated to pregnancy; cholestatic jaundice of pregnancy; liver tumors, benign or malignant, or active liver disease; uncontrolled hypertension.

Thromboembolic disorders: Discontinue if thrombosis or thromboembolism occurs.
Allergic reactions: Consider discontinuing if allergic reactions occur.
Decreased glucose tolerance: Monitor prediabetic and diabetic women receiving hydroxyprogesterone caproate injection.
Fluid retention: Monitor women with conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction.
Depression: Monitor women with a history of clinical depression; discontinue hydroxyprogesterone caproate injection if depression recurs.
Jaundice: Monitor women who develop jaundice while receiving hydroxyprogesterone caproate injection and consider whether the benefit of use warrants continuation.
Hypertension: Monitor women who develop hypertension while receiving hydroxyprogesterone caproate injection and consider whether the benefit of use warrants continuation.

Most common adverse reactions reported in ≥2% of subjects and at a higher rate in the hydroxyprogesterone caproate injection group than in the control group were injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%), and diarrhea (2%). For the most serious adverse reactions to the use of progestins, see Warnings and Precautions.

Postmarketing Experience 
The following adverse reactions have been identified during post approval use of hydroxyprogesterone caproate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a whole: Local injection site reactions (including erythema, urticaria, rash, irritation, hypersensitivity, warmth); fatigue; fever; hot flashes/flushes
Digestive disorders: Vomiting
Infections: Urinary tract infection
Nervous system disorders: Headache, dizziness
Pregnancy, puerperium and perinatal conditions: Cervical incompetence, premature rupture of membranes
Reproductive system and breast disorders: Cervical dilation, shortened cervix
Respiratory disorders: Dyspnea, chest discomfort
Skin: Rash

Data from the placebo-controlled clinical trial and the infant follow-up safety study did not show a difference in adverse developmental outcomes between children of hydroxyprogesterone caproate injection-treated women and children of control subjects. However, these data are insufficient to determine a drug-associated risk of adverse developmental outcomes as none of the hydroxyprogesterone caproate injection-treated women received the drug during the first trimester of pregnancy.

Lactation Risk Summary: Low levels of progestins are present in human milk with the use of progestin containing products, including hydroxyprogesterone caproate. Published studies have reported no adverse effects of progestins on the breastfed child or on milk production.

Pediatric Use: Hydroxyprogesterone caproate injection is not indicated for use in women under 16 years of age.

Hepatic Impairment: Hydroxyprogesterone caproate injection is extensively metabolized and hepatic impairment may reduce the elimination of hydroxyprogesterone caproate injection.

In the case of overdosage, the patient should be treated symptomatically.

For additional Safety Information, please see Full Prescribing Information.

You are encouraged to report Adverse Drug Events to American Regent Inc. at 1-800-734-9236 or to the FDA by visiting or calling 1-800-FDA-1088.

REF-0782 7/2019